Haemalogix Raises $10 Million to Advance Multiple Myeloma Treatments
HaemaLogiX Pty Ltd, a clinical stage biotech company developing novel immuno-oncology and immune therapies for patients with blood cancers, is pleased to both announce the close of a fully subscribed $10 million placement to sophisticated investors and welcomes Platinum Asset Management as core new institutional investor within its Platinum International Health Care Fund. Bryce Carmine, HaemaLogiX Chairman…